Related Experiment Video
Updated: May 12, 2026
12:49
Isolation, Culture, and Functional Characterization of Adult Mouse Cardiomyoctyes
Published on: September 24, 2013
Interference with ERK(Thr188) phosphorylation impairs pathological but not physiological cardiac hypertrophy
Catharina Ruppert1, Katharina Deiss, Sebastian Herrmann
1Institute of Pharmacology and Toxicology, University of Würzburg, 97078 Würzburg, Germany.
Summary
Targeting ERK(Thr188) autophosphorylation inhibits pathological cardiac hypertrophy without causing cell death. This specific approach offers a potential therapeutic strategy for heart conditions like aortic valve stenosis.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Signal Transduction
Background:
- Extracellular signal-regulated kinases 1 and 2 (ERK1/2) are key mediators of cardiac hypertrophy, a condition targeted for therapy.
- Direct ERK1/2 inhibition worsens cardiomyocyte death and heart function, necessitating alternative strategies.
- ERK(Thr188) autophosphorylation was identified as a critical regulatory site in ERK1/2-mediated cardiac hypertrophy.
Purpose of the Study:
- To investigate if interfering with ERK(Thr188) phosphorylation can impair pathological cardiac hypertrophy without inducing cardiomyocyte death.
- To analyze the impact of blocking ERK(Thr188) signaling on both pathological and physiological cardiac growth.
- To assess the clinical relevance of ERK(Thr188) phosphorylation in patients with aortic valve stenosis.
Main Methods:
- Utilized a dominant-negative mutant ERK2(T188A) in isolated cardiomyocytes and in vivo mouse models.
- Assessed cardiomyocyte hypertrophy and cell survival in response to hypertrophic stimuli and pressure overload.
- Examined physiological cardiac growth during aging and exercise.
- Measured ERK(Thr188) phosphorylation levels in patient samples with varying degrees of aortic valve stenosis.
Main Results:
- The ERK2(T188A) mutant significantly attenuated cardiomyocyte hypertrophy induced by phenylephrine and pressure overload.
- ERK2(T188A) did not compromise antiapoptotic ERK1/2 signaling or overall cardiac function.
- Physiological cardiac growth, including age-related and exercise-induced hypertrophy, was unaffected by ERK2(T188A).
- ERK(Thr188) phosphorylation was significantly elevated in rapidly progressing aortic valve stenosis patients compared to slowly progressing cases.
Conclusions:
- Interference with ERK(Thr188) phosphorylation selectively inhibits pathological cardiac hypertrophy.
- This strategy preserves essential antiapoptotic ERK1/2 signaling and physiological cardiac function.
- Elevated ERK(Thr188) phosphorylation in severe aortic valve stenosis highlights its role in disease progression.
- Targeting ERK(Thr188) phosphorylation presents a promising therapeutic avenue for selective treatment of pathological cardiac hypertrophy.
Related Concept Videos
01:26Cellular Adaptation II: Hypertrophy
Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...